The forecast for cardiovascular system medicine sales in Canada between 2024 and 2028 indicates a steady decline. In 2023, actual sales stood at around CAD 3.04 billion, maintaining the same level in 2024. However, from 2025 onwards, a decreasing trend is observed, with a year-on-year decline of approximately 3% to 4% each year. By 2028, sales are projected to reach CAD 2.7 billion. This results in a compound annual growth rate (CAGR) of approximately -2.9% over five years.

Future trends to watch for in cardiovascular medicine sales include:

Potential impacts of emerging medical technologies and innovations in treatment.
Shifts in healthcare policies and reimbursement landscapes that may alter medicine affordability and accessibility.
Demographic shifts, such as aging populations, which could influence demand patterns.
Increased competition from generic and alternative therapies.